ArticleCellular oncology (Dordrecht, Netherlands)2021
A comprehensive prognostic signature for glioblastoma patients based on transcriptomics and single cell sequencing.
Article in Cellular oncology (Dordrecht, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Crosstalk Between CTSBAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Unraveling the Molecular Mechanisms of Glioma Recurrence: A Study Integrating Single-Cell and Spatial Transcriptomics.Annals of clinical and translational neurology · 2026Article
- Deciphering the glioblastoma microenvironmental landscape with multi-modal radiogenomics to guide prognosis and personalized therapy.Journal of translational medicine · 2026Article
- Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases.International journal of molecular sciences · 2025Review
- Targeting membrane contact sites to mediate lipid dynamics: innovative cancer therapies.Cell communication and signaling : CCS · 2025Review
- COL8A1 as a pro-inflammatory mediator bridges immune evasion and therapy resistance in glioma.Frontiers in immunology · 2025Article
- DNAJC1 facilitates glioblastoma progression by promoting extracellular matrix reorganization and macrophage infiltration.Journal of cancer research and clinical oncology · 2024Article
- TMO-Net: an explainable pretrained multi-omics model for multi-task learning in oncology.Genome biology · 2024Article
- Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas.Current issues in molecular biology · 2024Review
- Single-cell and spatial transcriptome assays reveal heterogeneity in gliomas through stress responses and pathway alterations.Frontiers in immunology · 2024Article
- Genetic profiling in radiotherapy: a comprehensive review.Frontiers in oncology · 2024Review
- Role of long pentraxin PTX3 in cancer.Clinical and experimental medicine · 2023Review
- Exploring the prognostic function of TMB-related prognostic signature in patients with colon cancer.BMC medical genomics · 2023Article
- System analysis based on the T cell exhaustion‑related genes identifies CD38 as a novel therapy target for ovarian cancer.Oncology research · 2023Article
- Multi-omics analysis of LAMB3 as a potential immunological and biomarker in pan-cancer.Frontiers in molecular biosciences · 2023Article
- Insights into the Relationship between Pentraxin-3 and Cancer.International journal of molecular sciences · 2022Review
- Role of Seipin in Human Diseases and Experimental Animal Models.Biomolecules · 2022Review
- Article
- Construction of an immune-related gene signature for the prognosis and diagnosis of glioblastoma multiforme.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeGlioblastoma (GBM) is the most common and deadly brain tumor. We aimed to reveal potential prognostic GBM marker genes, elaborate their functions, and build an effective a prognostic model for GBM patients.
methodsThrough data mining of The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA), we screened for significantly differentially expressed genes (DEGs) to calculate risk scores for individual patients. Published data of somatic mutation and copy number variation profiles were analyzed for distinct genomic alterations associated with risk scores. In addition, single-cell sequencing was used to explore the biological functions of the identified prognostic marker genes. By combining risk scores and other clinical features, we built a comprehensive prognostic GBM model.
resultsSeven DEGs (CLEC5A, HOXC6, HOXA5, CCL2, GPRASP1, BSCL2 and PTX3) were identified as being prognostic for GBM. Expression of these genes was confirmed in different GBM cell lines using real-time PCR. Risk scores calculated from the seven DEGs revealed prognostic value irrespective of other clinical factors, including IDH mutation status, and were negatively correlated with TP53 expression. The prognostic genes were found to be associated with tumor proliferation and progression based on pseudo-time analysis in neoplastic cells. A final prognostic model was developed and validated with a good performance, especially in geriatric GBM patients.
conclusionsUsing genetic profiles, age, IDH mutation status, and chemotherapy and radiotherapy, we constructed a comprehensive prognostic model for GBM patients. The model has a good performance, especially in geriatric GBM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.